UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Long-Acting HIV Drugs for Treatment and Prevention

Annual review of medicine, 2019-01, Vol.70 (1), p.137-150

2019

Volltextzugriff (PDF)

Clinical Characteristics of Covid-19 in New York City

The New England journal of medicine, 2020-06, Vol.382 (24), p.2372-2374

2020

Volltextzugriff (PDF)

Raltegravir: The First HIV Type 1 Integrase Inhibitor

Clinical infectious diseases, 2009-04, Vol.48 (7), p.931-939

2009

Volltextzugriff (PDF)

Severe Covid-19

The New England journal of medicine, 2020-12, Vol.383 (25), p.2451-2460

2020

Volltextzugriff (PDF)

Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo

PloS one, 2009-05, Vol.4 (5), p.e5683-e5683

2009

Volltextzugriff (PDF)

Early versus Standard Antiretroviral Therapy for HIV-Infected Adults in Haiti

The New England journal of medicine, 2010-07, Vol.363 (3), p.257-265

2010

Volltextzugriff (PDF)

Pre-existing Minority Drug-Resistant HIV-1 Variants, Adherence, and Risk of Antiretroviral Treatment Failure

The Journal of infectious diseases, 2010-03, Vol.201 (5), p.662-671

2010

Volltextzugriff (PDF)

Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease

PloS one, 2020-07, Vol.15 (7), p.e0236778

2020

Volltextzugriff (PDF)

CCR5 Antagonism in HIV Infection: Current Concepts and Future Opportunities

Annual review of medicine, 2012-01, Vol.63 (1), p.81-93

2012

Volltextzugriff (PDF)

Mass spectrometry imaging of hair identifies daily maraviroc adherence in HPTN 069/ACTG A5305

PloS one, 2023-06, Vol.18 (6), p.e0287449-e0287449

2023

Volltextzugriff (PDF)

Phase 2 Study of the Safety and Efficacy of Vicriviroc, a CCR5 Inhibitor, in HIV-1-Infected, Treatment-Experienced Patients: AIDS Clinical Trials Group 5211

The Journal of infectious diseases, 2007-07, Vol.196 (2), p.304-312

2007

Volltextzugriff (PDF)

The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States

Clinical infectious diseases, 2016-03, Vol.62 (6), p.784-791

2016

Volltextzugriff (PDF)

Tissue specificity-aware TWAS (TSA-TWAS) framework identifies novel associations with metabolic, immunologic, and virologic traits in HIV-positive adults

PLoS genetics, 2021-04, Vol.17 (4), p.e1009464

2021

Volltextzugriff (PDF)

Preexisting Resistance to Nonnucleoside Reverse-Transcriptase Inhibitors Predicts Virologic Failure of an Efavirenz-Based Regimen in Treatment-Naive HIV-1–Infected Subjects

The Journal of infectious diseases, 2008-03, Vol.197 (6), p.867-870

2008

Volltextzugriff (PDF)

Effect of CYP2B6, ABCB1, and CYP3A5 Polymorphisms on Efavirenz Pharmacokinetics and Treatment Response: An AIDS Clinical Trials Group Study

The Journal of infectious diseases, 2010-09, Vol.202 (5), p.717-722

2010

Volltextzugriff (PDF)

Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals

Annals of internal medicine, 2005-11, Vol.143 (10), p.714

2005

Volltextzugriff (PDF)

HIV treatment and prevention 2019: current standards of care

Current opinion in HIV & AIDS, 2020-01, Vol.15 (1), p.4-12

2020

Volltextzugriff (PDF)

HIV Type 1 Chemokine Coreceptor Use among Antiretroviral-Experienced Patients Screened for a Clinical Trial of a CCR5 Inhibitor: AIDS Clinical Trial Group A5211

Clinical infectious diseases, 2007-02, Vol.44 (4), p.591-595

2007

Volltextzugriff (PDF)

No change in health-related quality of life for at-risk U.S. women and men starting HIV pre-exposure prophylaxis (PrEP): Findings from HPTN 069/ACTG A5305

PloS one, 2018-12, Vol.13 (12), p.e0206577-e0206577

2018

Volltextzugriff (PDF)

Pharmacogenetics of Plasma Efavirenz Exposure after Treatment Discontinuation: An Adult AIDS Clinical Trials Group Study

Clinical infectious diseases, 2006-02, Vol.42 (3), p.401-407

2006

Volltextzugriff (PDF)

Barriers to Uptake of Long-Acting Antiretroviral Products for Treatment and Prevention of Human Immunodeficiency Virus (HIV) in High-Income Countries

Clinical infectious diseases, 2022-11, Vol.75 (Suppl 4), p.S541-S548

2022

Volltextzugriff (PDF)

In Vivo Emergence of Vicriviroc Resistance in a Human Immunodeficiency Virus Type 1 Subtype C-Infected Subject

Journal of Virology, 2008-08, Vol.82 (16), p.8210-8214

2008

Volltextzugriff (PDF)

Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117

Nature (London), 2015-06, Vol.522 (7557), p.487-491

2015

Volltextzugriff (PDF)

Selecting Treatments During an Infectious Disease Pandemic: Chasing the Evidence

Annals of internal medicine, 2021-10, Vol.174 (10), p.1464-1465

2021

Volltextzugriff (PDF)

1 – 25 von 230

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(208)
Mit Volltextzugriff
(158)

Publikationsform

Sprache

Englisch
(230)
Portugiesisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(164)
Humans
(155)
Life Sciences & Biomedicine
(152)
Infectious Diseases
(130)
Hiv Infections - Drug Therapy
(112)
Hiv
(107)
Male
(92)
Immunology
(87)
Adult
(86)
Female
(85)
Biological And Medical Sciences
(83)
Human Immunodeficiency Virus
(82)
Medical Sciences
(79)
Viral Diseases
(67)
Anti-Hiv Agents - Therapeutic Use
(66)
Microbiology
(66)
Human Viral Diseases
(64)
Viral Diseases Of The Lymphoid Tissue And The Blood. Aids
(62)
Virology
(59)
Hiv Infections - Virology
(58)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Long-Acting HIV Drugs for Treatment and Prevention

Clinical Characteristics of Covid-19 in New York City

Raltegravir: The First HIV Type 1 Integrase Inhibitor

Severe Covid-19

Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo

Early versus Standard Antiretroviral Therapy for HIV-Infected Adults in Haiti

Pre-existing Minority Drug-Resistant HIV-1 Variants, Adherence, and Risk of Antiretroviral Treatment Failure

Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease

CCR5 Antagonism in HIV Infection: Current Concepts and Future Opportunities

Mass spectrometry imaging of hair identifies daily maraviroc adherence in HPTN 069/ACTG A5305

Phase 2 Study of the Safety and Efficacy of Vicriviroc, a CCR5 Inhibitor, in HIV-1-Infected, Treatment-Experienced Patients: AIDS Clinical Trials Group 5211

The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States

Tissue specificity-aware TWAS (TSA-TWAS) framework identifies novel associations with metabolic, immunologic, and virologic traits in HIV-positive adults

Preexisting Resistance to Nonnucleoside Reverse-Transcriptase Inhibitors Predicts Virologic Failure of an Efavirenz-Based Regimen in Treatment-Naive HIV-1–Infected Subjects

Effect of CYP2B6, ABCB1, and CYP3A5 Polymorphisms on Efavirenz Pharmacokinetics and Treatment Response: An AIDS Clinical Trials Group Study

Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals

HIV treatment and prevention 2019: current standards of care

HIV Type 1 Chemokine Coreceptor Use among Antiretroviral-Experienced Patients Screened for a Clinical Trial of a CCR5 Inhibitor: AIDS Clinical Trial Group A5211

No change in health-related quality of life for at-risk U.S. women and men starting HIV pre-exposure prophylaxis (PrEP): Findings from HPTN 069/ACTG A5305

Pharmacogenetics of Plasma Efavirenz Exposure after Treatment Discontinuation: An Adult AIDS Clinical Trials Group Study

Barriers to Uptake of Long-Acting Antiretroviral Products for Treatment and Prevention of Human Immunodeficiency Virus (HIV) in High-Income Countries

In Vivo Emergence of Vicriviroc Resistance in a Human Immunodeficiency Virus Type 1 Subtype C-Infected Subject

Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117

Combination therapy with anti-HIV-1 antibodies maintains viral suppression

Selecting Treatments During an Infectious Disease Pandemic: Chasing the Evidence

Suchergebnisse filtern